Innovation is being stifled – Lilly chief executive
February 10, 2011Research and Development, Sales and Marketing Economist 2011 Pharma Summit, US health reforms, healthcare costs, healthcare reform, lilly
Supporting medical innovation should be a fundamental requirement of healthcare reforms, but current public policies are failing to do this, …
Digital Pharma: This is how pharma is using digital
February 10, 2011Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Android, Digital Pharma blog, Facebook, Twitter, disease awareness campaigns, ipad, iphone, social media
Pharma’s use of digital tools, from mobile apps to online campaigns to social media channels, is increasing all the time …
Amarin expands US operations
February 10, 2011Sales and Marketing AMR101, Amarin, Paul Huff, high cholesterol
Dublin-based biopharmaceutical company Amarin is to increase its US presence by setting up sales and marketing headquarters in New Jersey. …
WHO wants narcolepsy link with swine flu vaccine investigated
February 10, 2011Research and Development, Sales and Marketing Finland Institute, GSK, GlaxoSmithKline, Pandemrix, narcolepsy, swine flu
The World Health Organisation has called for further investigation into GSK’s swine flu vaccine link to sleeping disorder narcolepsy, following …
Dr Mikael von Euler moves to Oncos Therapeutics
February 10, 2011Research and Development Dr Mikael von Euler, Oncos Therapeutics, appointment, research and development
Finnish biotech company Oncos Therapeutics has appointed Dr Mikael von Euler as chief medical officer. He has more than 20 …
Alliance concerned over NHS competition reforms
February 10, 2011Health and Social Care Bill, NHS, NHS Alliance, NHS reforms
The NHS Alliance has called on the Government to clarify major issues around the Health and Social Care Bill which …
Generics force Sanofi into standstill
February 9, 2011Sales and Marketing 2010 pharma results, Jevtana, Multaq, Sanofi, Sanofi-Aventis, generics
An onslaught of generic competition combined with healthcare cuts in the US and Europe meant Sanofi-Aventis’ revenues were brought to …
Shire bags senior research execs from GSK and Abbott
February 9, 2011Research and Development Dr Lawson Macartney, Dr Mario Saltarelli, Shire, appointment, recruitment, research and development
Shire has strengthened its speciality pharmaceuticals business with the appointment of senior research executives from GlaxoSmithKline and Abbott. Dr Lawson …
Pharma-NHS diabetes project begins
February 9, 2011Sales and Marketing AstraZeneca, Lilly UK, MSD, NHS, Nottingham, Novartis, Novo Nordisk, Pfizer, Sanofi-Aventis, joint working
A joint venture between the NHS, charities and the pharma sector has begun in Nottingham to help treat the city’s …
Teva surges ahead
February 9, 2011Sales and Marketing 2010 pharma results, Copaxone, Teva, Teva Pharmaceutical
Generics giant Teva enjoyed a strong year of growth in 2010, lifted by the acquisition of Ratiopharm, patent expiries of …
Dr Matthias joins Noxxon Pharma
February 9, 2011Research and Development Dr Matthias Baumann, Noxxon Pharma, appointment, research and development
Berlin-based biotech Noxxon Pharma has appointed Dr Matthias Baumann as chief medical officers. He joins from Focus Clinical Drug Development, …
Melanoma: intense competition to be the next milestone treatment
February 9, 2011Research and Development BRAF V600 mutation, Cancer, Tasigna, cancer research, melanoma, tremelimumab
A flurry of new data has emerged in the recent months from an industry-wide pipeline of cancer drugs which could …
AZ-Targacept depression candidate moves into phase IIb
February 9, 2011Research and Development AZ, AstraZeneca, TC-5214, Targacept, depression, major depressive disorder
AstraZeneca and Targacept have begun a phase IIb trial of TC-5214 as a ‘switch’ monotherapy for patients with depression. The …
Early diagnosis key to UK cancer ambition
February 8, 2011Cancer, NHS, NICE
A series of quality standards on cancer care is to be drawn up by NICE as part of a new …
Genzyme to divest pharma intermediates business
February 8, 2011Manufacturing and Production Cerezyme, Corden Pharma Switzerland, Corden Pharma group, Genzyme, International Chemical Investors Group, Sekisui Chemical Co, imiglucerase
Genzyme has agreed to sell off its pharmaceutical intermediates business to International Chemical Investors Group, a holding company which has …
Pharmaceutical facility news in brief
February 8, 2011Manufacturing and Production Baxter International, Famar, Lannett, Qatar Pharma, Sanofi-Aventis, Takeda Pharmaceutical Co
A round-up of news involving manufacturing facilities includes updates from Takeda, Famar/Sanofi, Qatar Pharma, Lannett and Baxter. Takeda Pharmaceutical Co …
Roche eyes ovarian cancer expansion for Avastin
February 8, 2011Sales and Marketing Cancer, Roche, avastin, bevacizumab, ovarian cancer
Roche has submitted an EU marketing authorisation for Avastin for the treatment of ovarian cancer and plans to file the …
Stabilitech appoints new commercial director
February 8, 2011Manufacturing and Production Donna Hackett, Stabilitch, appointment, manufacturing and production
Donna Hackett joins stabilisation company Stabilitch as commercial director. She has 20 years pharma experience, most recently at pre-clinical, clinical …
Teva plant in Israel cited by FDA, expands in Americas
February 8, 2011Manufacturing and Production Corporacion Infarmasa, FDA, Peru, Teva, Teva Pharmaceutical, generics, generics manufacturing, manufacturing compliance
A manufacturing facility in Jerusalem operated by Teva Pharmaceutical failed to pass muster in an FDA inspection, prompting a warning …
Avecia Biotech sold to Nitto Denko
February 8, 2011Manufacturing and Production Avecia, Avecia Biologics, Avecia Biotechnology, Nitto Denko
Avecia Biotechnology, which focuses mainly on the development and manufacturing of oligonuceotide medicines, has been acquired by Japanese firm Nitto …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
